A Phase 2 interventional study of N-acetylcysteine (NAC) in Drug-Induced Liver Injury and Tuberculosis, sponsored by RSUP Persahabatan. Completed at 1 site in Indonesia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by RSUP Persahabatan · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Anti-tuberculosis drug-induced liver injury (AT-DILI) is a common side effect of tuberculosis (TB) treatment. It often forces TB drugs to be stopped temporarily, which may reduce treatment success. N-acetylcysteine (NAC) is an antioxidant that helps the body make glutathione and may help the liver recover. Most previous studies tested NAC to prevent liver injury rather than to treat liver injury that has already occurred.
This study aimed to find out whether oral NAC, given as an adjuvant therapy, improves liver function and nausea-vomiting in hospitalized adults with drug-susceptible TB who developed AT-DILI. Participants were randomly assigned to receive effervescent NAC 600 mg twice daily for 7 days or no NAC. Liver tests (ALT, AST, and total bilirubin) were measured on days 0, 3, 6, and 9, and nausea and vomiting were assessed daily from day 0 to day 9.
Design: open-label, randomized, parallel-group clinical trial at Persahabatan National Respiratory Referral Hospital, Jakarta, Indonesia, from February to September 2026.
AT-DILI definition: ALT/AST ≥3 times the upper limit of normal (ULN) with symptoms, and/or ≥5 times ULN without symptoms, and/or total bilirubin >2 mg/dL.
Procedures: Patients were screened using baseline laboratory results at hospital admission (day 0). After confirmation of TB diagnosis, AT-DILI, eligibility criteria, and written informed consent, baseline ALT, AST, total bilirubin, and clinical characteristics were recorded. Participants were then randomized to (A) effervescent NAC 600 mg twice daily or (B) no NAC. The intervention was given for 7 days. Participants were hospitalized for at least 6 days and had a follow-up visit on day 9. ALT, AST, and total bilirubin were measured on days 3, 6, and 9 (day 9 tests were done at the outpatient visit or during hospitalization). Nausea and vomiting severity was assessed daily from day 0 to day 9 using the Rhodes Index of Nausea, Vomiting, and Retching (RINVR); for participants discharged by day 6, days 7 and 8 were assessed at the day 9 visit.
Sample size: minimum 21 participants per group (two-sided alpha 0.05, power 80%, SD 40 U/L, minimal clinically meaningful difference 35 U/L), using total sampling during the study period.
Statistical analysis: normality tested with Shapiro-Wilk. Changes in ALT, AST, and total bilirubin at days 3, 6, and 9 were compared between groups using the unpaired t-test or Mann-Whitney test. Daily nausea-vomiting severity was analyzed with generalized estimating equations (GEE) with a cumulative logit link. Potential confounders: age, sex, nutritional status (BMI), and type 2 diabetes mellitus. Analyses were performed with SPSS version 26.0.
81 studies on the registry are indexed under Chemical and Drug Induced Liver Injury; 21 are open to participants now.
This study's enrollment of 28 is below the median of 80 across 40 interventional studies indexed under Chemical and Drug Induced Liver Injury.
Browse Chemical and Drug Induced Liver Injury studies →RSUP Persahabatan is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received effervescent N-acetylcysteine 600 mg orally twice daily for 7 days.
Drug: N-acetylcysteine (NAC)
Participants did not receive N-acetylcysteine.
Effervescent N-acetylcysteine 600 mg tablet, taken orally twice daily (2 × 600 mg) for 7 days.
Also known as: Acetylcysteine, NAC
Change in Serum Alanine Aminotransferase (ALT/SGPT)
Change in serum ALT (U/L) from baseline (day 0) to day 3, day 6, and day 9, compared between the NAC and no-NAC groups.
Time frame: Baseline (day 0), day 3, day 6, and day 9
Change in Serum Aspartate Aminotransferase (AST/SGOT)
Change in serum AST (U/L) from baseline (day 0) to day 3, day 6, and day 9, compared between the NAC and no-NAC groups.
Time frame: Baseline (day 0), day 3, day 6, and day 9
Change in Serum Total Bilirubin
Change in serum total bilirubin (mg/dL) from baseline (day 0) to day 3, day 6, and day 9, compared between the NAC and no-NAC groups.
Time frame: Baseline (day 0), day 3, day 6, and day 9
Severity of Nausea and Vomiting
Daily severity of nausea and vomiting assessed with the Rhodes Index of Nausea, Vomiting, and Retching (RINVR), categorized as normal, mild, moderate, severe, or very severe.
Time frame: Daily from day 0 to day 9
Plan to share: No — Individual participant data will not be shared publicly. The study was a small, single-center rial, and participants consented to the use of their data for this study only. Data contain clinical information from hospitalized patients and are kept confidential in accordance with the approval of the Health Research Ethics Committee, Persahabatan Hospital. Aggregate results will be reported in the thesis and in a peer-reviewed publication.
Ran from Feb 2026 to primary completion in Sep 2026, 7 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetylcysteine
Chemical and Drug Induced Liver Injury →
RSUP Persahabatan